Cargando…

Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2

Detalles Bibliográficos
Autores principales:	Lee, Kyung-Yil, Rhim, Jung-Woo, Kang, Jin-Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Pediatric Society 2020
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170790/ https://www.ncbi.nlm.nih.gov/pubmed/32272008 http://dx.doi.org/10.3345/cep.2020.00290

Ejemplares similares

Immunopathogenesis of COVID-19 and early immunomodulators
por: Lee, Kyung-Yil, et al.
Publicado: (2020)

Early Corticosteroid Therapy for Mycoplasma pneumoniae Pneumonia Irrespective of Used Antibiotics in Children
por: Yang, Eun-Ae, et al.
Publicado: (2019)

Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1 influenza virus
por: Kil, Hong-Ryang, et al.
Publicado: (2011)

Corticosteroid Therapy in Severe Cases of Pneumonia Caused by SARS-CoV-2
por: Alves, João, et al.
Publicado: (2022)

Early Additional Immune-Modulators for Mycoplasma pneumoniae Pneumonia in Children: An Observation Study
por: Youn, You-Sook, et al.
Publicado: (2014)

Early Serologic Diagnosis of Mycoplasma pneumoniae Pneumonia: An Observational Study on Changes in Titers of Specific-IgM Antibodies and Cold Agglutinins
por: Lee, Sung-Churl, et al.
Publicado: (2016)

Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza virus infections: A need for early immune-modulators for severe cases
por: Lee, Kyung-Yil, et al.
Publicado: (2011)

Epidemiological relationship between Mycoplasma pneumoniae pneumonia and recurrent wheezing episode in children: an observational study at a single hospital in Korea
por: Rhim, Jung Woo, et al.
Publicado: (2019)

Macrolide-Resistant and Macrolide-Sensitive Mycoplasma pneumoniae Pneumonia in Children Treated Using Early Corticosteroids
por: Han, Hye Young, et al.
Publicado: (2021)

Additional corticosteroids or alternative antibiotics for the treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia
por: Yang, Eun-Ae, et al.
Publicado: (2017)

Role of the early secretory pathway in SARS-CoV-2 infection
por: Sicari, Daria, et al.
Publicado: (2020)

Etiological and pathophysiological enigmas of severe coronavirus disease 2019, multisystem inflammatory syndrome in children, and Kawasaki disease
por: Rhim, Jung-Woo, et al.
Publicado: (2021)

Preemptive kidney transplantation: why, when, and how?
por: Moura, Ana Flávia, et al.
Publicado: (2022)

Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years
por: Kim, Eun-Kyung, et al.
Publicado: (2015)

Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection
por: Netea, Mihai G., et al.
Publicado: (2020)

Early Confirmation of Mycoplasma pneumoniae Infection by Two Short-Term Serologic IgM Examination
por: Jeon, Ha Eun, et al.
Publicado: (2021)

Preemptive SARS patents
por: Brickley, Peg
Publicado: (2003)

Superantigens and SARS-CoV-2
por: Hamdy, Adam, et al.
Publicado: (2022)

Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia
por: Youn, You-Sook, et al.
Publicado: (2010)

Role of the Pangolin in Origin of SARS-CoV-2: An Evolutionary Perspective
por: Gupta, Shishir K., et al.
Publicado: (2022)

SARS-CoV-2 organising pneumonia: ‘Has there been a widespread failure to identify and treat this prevalent condition in COVID-19?’
por: Kory, Pierre, et al.
Publicado: (2020)

Role of inactivated SARS-CoV-2 vaccine induced T cell responses in ameliorating COVID-19 severity
por: Huang, Hongming, et al.
Publicado: (2023)

Pharmacogenomics cascade testing (PhaCT): a novel approach for preemptive pharmacogenomics testing to optimize medication therapy
por: Roosan, Don, et al.
Publicado: (2020)

Immunomodulation by endothelial cells — partnering up with the immune system?
por: Amersfoort, Jacob, et al.
Publicado: (2022)

The role of immunomodulators in treatment-resistant depression: case studies
por: Beckett, Charles W., et al.
Publicado: (2022)

Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature
por: Bacca, Erica, et al.
Publicado: (2021)

Equitable distribution of SARS-CoV-2 tests
por: Garcia-Bereguiain, Miguel Angel, et al.
Publicado: (2022)

SARS-CoV-2 and Arthropods: A Review
por: Higgs, Stephen, et al.
Publicado: (2022)

SARS-CoV-2 S Glycoprotein Stabilization Strategies
por: Pedenko, Borys, et al.
Publicado: (2023)

Adjunctive immunomodulation in severe community-acquired pneumonia
por: Bradley, James, et al.
Publicado: (2023)

Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease()
por: González-Castro, A., et al.
Publicado: (2022)

Immunomodulation as a neuroprotective strategy after spinal cord injury
por: Monteiro, Susana, et al.
Publicado: (2018)

Low-dose and oral exposure to SARS-CoV-2 may help us understand and prevent severe COVID-19
por: Hausdorff, William P., et al.
Publicado: (2021)

Approaches and Challenges in SARS-CoV-2 Vaccine Development
por: Dagotto, Gabriel, et al.
Publicado: (2020)

Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity
por: Burtscher, Johannes, et al.
Publicado: (2020)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Environmental factors and their role in the transmission of SARS-CoV-2
por: Maciorowski, Dawid, et al.
Publicado: (2021)

Adapting Serosurveys for the SARS-CoV-2 Vaccine Era
por: Duarte, Nathan, et al.
Publicado: (2021)

SARS‐CoV‐2 Omicron variant: Characteristics and prevention
por: He, Xuemei, et al.
Publicado: (2021)

Innate Immune Response in SARS-CoV-2 Infection
por: Schiuma, Giovanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_i54783n46dc4fadm49k8gke1j0